US nod for CSL Behring’s Hizentra

19th March 2018 Uncategorised 0

US regulators have cleared CSL Behring’s Hizentra for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder affecting the peripheral nerves that can cause permanent nerve damage.

More: US nod for CSL Behring’s Hizentra
Source: News